Literature DB >> 22226125

My child is unique; the pharmacokinetics are universal.

Brian J Anderson1.   

Abstract

The pharmacokinetic (PK) parameters that are important for dosing (e.g., clearance and volume) are well known. They are used in universal mathematical formulae that describe the time course of drug concentration. Additional formulae can be used to describe major covariate effects in children, such as size and maturation. PK parameters describing the time-concentration profile of a drug after administration are those for a typical individual in a population. These parameters are associated with variability. Further, any one individual may not be typical of the population studied. While size and maturation are two important considerations in children and assist with dosing estimation, there are also a number of additional PK covariates (e.g., organ function, disease, drug interactions, pharmacogenetics), and identifying these sources of variability allows us to individualize drug dose. Pharmacology is not simply an application of PK, and determinants of drug dose also require an understanding of the variability associated with pharmacodynamic response and a balancing of beneficial effects against unwanted effects. Each child is unique in this respect.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22226125     DOI: 10.1111/j.1460-9592.2011.03788.x

Source DB:  PubMed          Journal:  Paediatr Anaesth        ISSN: 1155-5645            Impact factor:   2.556


  5 in total

Review 1.  Tuberculosis in children with severe acute malnutrition.

Authors:  Bryan J Vonasek; Kendra K Radtke; Paula Vaz; W Chris Buck; Chishala Chabala; Eric D McCollum; Olivier Marcy; Elizabeth Fitzgerald; Alexander Kondwani; Anthony J Garcia-Prats
Journal:  Expert Rev Respir Med       Date:  2022-02-28       Impact factor: 4.300

Review 2.  Neonatal clinical pharmacology.

Authors:  Karel Allegaert; Marc van de Velde; John van den Anker
Journal:  Paediatr Anaesth       Date:  2013-04-26       Impact factor: 2.556

Review 3.  Population pharmacokinetic analysis during the first 2 years of life: an overview.

Authors:  Amélie Marsot; Audrey Boulamery; Bernard Bruguerolle; Nicolas Simon
Journal:  Clin Pharmacokinet       Date:  2012-12       Impact factor: 6.447

4.  Pain in Intellectually Disabled Children: Towards Evidence-Based Pharmacotherapy?

Authors:  Abraham J Valkenburg; Tom G de Leeuw; Monique van Dijk; Dick Tibboel
Journal:  Paediatr Drugs       Date:  2015-10       Impact factor: 3.022

Review 5.  Neonatal anesthesia: how we manage our most vulnerable patients.

Authors:  Si Ra Bang
Journal:  Korean J Anesthesiol       Date:  2015-09-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.